#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes


Until now, decisions about how to allocate ART have largely been based on maximising the therapeutic benefit of ART for patients. Since the results of the HPTN 052 study showed efficacy of antiretroviral therapy (ART) in preventing HIV transmission, there has been increased interest in the benefits of ART not only as treatment, but also in prevention. Resources for expanding ART in the short term may be limited, so the question is how to generate the most prevention benefit from realistic potential increases in the availability of ART. Although not a formal systematic review, here we review different ways in which access to ART could be expanded by prioritising access to particular groups based on clinical or behavioural factors. For each group we consider (i) the clinical and epidemiological benefits, (ii) the potential feasibility, acceptability, and equity, and (iii) the affordability and cost-effectiveness of prioritising ART access for that group. In re-evaluating the allocation of ART in light of the new data about ART preventing transmission, the goal should be to create policies that maximise epidemiological and clinical benefit while still being feasible, affordable, acceptable, and equitable.


Vyšlo v časopise: HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes. PLoS Med 9(7): e32767. doi:10.1371/journal.pmed.1001258
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001258

Souhrn

Until now, decisions about how to allocate ART have largely been based on maximising the therapeutic benefit of ART for patients. Since the results of the HPTN 052 study showed efficacy of antiretroviral therapy (ART) in preventing HIV transmission, there has been increased interest in the benefits of ART not only as treatment, but also in prevention. Resources for expanding ART in the short term may be limited, so the question is how to generate the most prevention benefit from realistic potential increases in the availability of ART. Although not a formal systematic review, here we review different ways in which access to ART could be expanded by prioritising access to particular groups based on clinical or behavioural factors. For each group we consider (i) the clinical and epidemiological benefits, (ii) the potential feasibility, acceptability, and equity, and (iii) the affordability and cost-effectiveness of prioritising ART access for that group. In re-evaluating the allocation of ART in light of the new data about ART preventing transmission, the goal should be to create policies that maximise epidemiological and clinical benefit while still being feasible, affordable, acceptable, and equitable.


Zdroje

1. World Health Organization, Joint United Nations Programme on HIV/AIDS, United Nations Children's Fund 2011 Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011 Geneva World Health Organization Available: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. Accessed 13 December 2011

2. SadrWECohenMDeCockKBekkerLGKarimS 2011 PEPFAR Scientific Advisory Board recommendations for the Office of the US Global AIDS Coordinator: implications of HPTN 052 for PEPFAR's treatment programs Washington (District of Columbia) Office of the US Global AIDS Coordinator

3. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision Geneva World Health Organization

4. CohenJ 2011 Breakthrough of the year. HIV treatment as prevention. Science 334 1628

5. CohenMSChenYQMcCauleyMGambleTHosseinipourMC 2011 Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 493 505

6. HargroveJWHumphreyJH 2010 Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 24 F11 F14

7. 2010 Funding, other trends imperil global response to HIV/AIDS. AIDS Policy Law 25 4

8. GengEHBwanaMBKabakyengaJMuyindikeWEmenyonuNI 2010 Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS ONE 5 e14098 doi:10.1371/journal.pone.0014098

9. Panel on Antiretroviral Guidelines for Adults and Adolescents 2011 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Washington (District of Columbia) US Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 4 January 2012

10. European AIDS Clinical Society 2011 Guidelines: version 6—October 2011. Available: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf. Accessed 12 June 2012

11. DonnellDBaetenJMKiarieJThomasKKStevensW 2010 Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375 2092 2098

12. SterneJAMayMCostagliolaDde WolfFPhillipsAN 2009 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373 1352 1363

13. Van CutsemGFordNHildebrandKGoemaereEMatheeS 2011 Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS ONE 6 e14684 doi:10.1371/journal.pone.0014684

14. ClinicalTrials.gov 2012 Strategic Timing of Antiretroviral Treatment (START). Available: http://clinicaltrials.gov/ct2/show/NCT00867048. Accessed 4 January 2012

15. StoverJBollingerLAvilaC 2011 Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat 2011 738271

16. Joint United Nations Programme on HIV/AIDS 2011 UNAIDS world AIDS day report 2011: how to get to zero. faster. smarter. better Geneva Joint United Nations Programme on HIV/AIDS

17. RosenSFoxMP 2011 Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8 e1001056 doi:10.1371/journal.pmed.1001056

18. KranzerKZeineckerJGinsbergPOrrellCKalaweNN 2010 Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS ONE 5 e13801 doi:10.1371/journal.pone.0013801

19. NovitskyVNdung'uTWangRBussmannHChoncoF 2011 Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 25 1515 1522

20. MaloneJLSimmsTEGrayGCWagnerKFBurgeJR 1990 Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 3 144 151

21. RaboudJMHaleyLMontanerJSMurphyCJanuszewskaM 1995 Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Synd 10 Suppl 2 S67 S73

22. KatzITEssienTMarindaETGrayGEBangsbergDR 2011 Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 25 2177 2181

23. GeskusRBPrinsMHubertJBMiedemaFBerkhoutB 2007 The HIV RNA setpoint theory revisited. Retrovirology 4 65

24. FraserCHollingsworthTDChapmanRde WolfFHanageWP 2007 Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 104 17441 17446

25. BaetenJMKahleELingappaJRCoombsRWDelany-MoretlweS 2011 Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 3 77ra29

26. QuinnTCWawerMJSewankamboNSerwaddaDLiC 2000 Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342 921 929

27. FideliUSAllenSAMusondaRTraskSHahnBH 2001 Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17 901 910

28. LingappaJRHughesJPWangRSBaetenJMCelumC 2010 Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE 5 e12598 doi:10.1371/journal.pone.0012598

29. WangSXuFDemirciU 2010 Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv 28 770 781

30. de WolfFSpijkermanISchellekensPTLangendamMKuikenC 1997 AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 11 1799 1806

31. BoilyMCMâsseBAlsallaqRPadianNSEatonJW 2012 HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 9 e1001250 doi:10.1371/journal.pmed.1001250

32. NovitskyVWangRBussmannHLockmanSBaumM 2010 HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the “test-and-treat” approach to reduce HIV transmission. PLoS ONE 5 e10148 doi:10.1371/journal.pone.0010148

33. World Health Organization 2010 Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach—2010 version Geneva World Health Organization

34. SchoutenEJJahnAMidianiDMakombeSDMnthambalaA 2011 Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 378 282 284

35. Lesotho Ministry of Health and Social Welfare, ICF Macro 2010 Lesotho Demographic and Health Survey 2009. Calverton (Maryland): Ministry of Health and Social Welfare and ICF Macro

36. Malawi National Statistical Office, ICF Macro 2011 Malawi Demographic and Health Survey 2010. Calverton (Maryland): Malawi National Statistical Office and ICF Macro

37. Kenya National Bureau of Statistics, ICF Macro 2010 Kenya Demographic and Health Survey 2008-09. Calverton (Maryland): Kenya National Bureau of Statistics and ICF Macro

38. MugoNRHeffronRDonnellDWaldAWereEO 2011 Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 25 1887 1895

39. PatelDCortina-BorjaMThorneCNewellML 2007 Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 44 1647 1656

40. United Nations Department of Economic and Social Affairs Population Division 2011 World population prospects, the 2010 revision New York United Nations Available: http://esa.un.org/unpd/wpp/index.htm. Accessed 19 December 2011

41. EkoueviDKInwoleyATonwe-GoldBDanelCBecquetR 2007 Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses 23 1469 1474

42. Côte d'Ivoire Institut National de la Statistique, ORC Macro 2006 Enquête sur les indicateurs du sida, Côte d'Ivoire 2005. Calverton (Maryland): Côte d'Ivoire Institut National de la Statistique and ORC Macro

43. OladokunREAwoludeOBrownBJAdesinaOOladokunA 2010 Service uptake and performance of the prevention of mother-to-child transmission (PMTCT) programme in Ibadan, Nigeria. Afr J Med Med Sci 39 81 87

44. HolmesCNPrekoPOBoldsRBaidooJJollyPE 2008 Acceptance of voluntary counselling, testing and treatment for HIV among pregnant women in Kumasi, Ghana. Ghana Med J 42 8 15

45. GeddesRGiddyJButlerLMVan WykECrankshawT 2011 Dual and triple therapy to prevent mother-to-child transmission of HIV in a resource-limited setting—lessons from a South African programme. S Afr Med J 101 651 654

46. TorpeyKKabasoMKasondePDirksRBweupeM 2010 Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv Res 10 29

47. BanchenoWMMwanyumbaFMareverwaJ 2010 Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa. AIDS Care 22 1130 1135

48. HensenBBaggaleyRWongVJGrabbeKLShafferN 2011 Universal voluntary HIV testing in antenatal care settings: a review of the contribution of provider-initiated testing & counselling. Trop Med Int Health. E-pub ahead of print doi:10.1111/j.1365-3156.2011.02893.x

49. FergusonLGrantADWatson-JonesDKahawitaTOng'echJO 2012 Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health. E-pub ahead of print doi:10.1111/j.1365-3156.2012.02958.x

50. ToroPLKatyalMCarterRJMyerLEl-SadrWM 2010 Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS 24 515 524

51. BoylesTHWilkinsonLSLeisegangRMaartensG 2011 Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS ONE 6 e19201 doi:10.1371/journal.pone.0019201

52. BwirireLDFitzgeraldMZachariahRChikafaVMassaquoiM 2008 Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg 102 1195 1120

53. JohriMAko-ArreyD 2011 The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc 9 3

54. ShahMJohnsBAbimikuAWalkerDG 2011 Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 25 1903 1102

55. United Nations Development Programme 2010 What will it take to achieve the Millennium Development Goals? An international assessment New York United Nations Development Programme

56. van den AkkerTBemelmansMFordNJemuMDiggleE 2012 HIV care need not hamper maternity care: a descriptive analysis of integration of services in rural Malawi. BJOG 199 431 438

57. Abdool KarimSSNaidooKGroblerAPadayatchiNBaxterC 2010 Timing of initiation of antiretroviral drugs during tuberculosis therapy. New Engl J Med 362 697 706

58. World Health Organization 2011 Global tuberculosis control: WHO report 2011 Geneva World Health Organization

59. GolettiDWeissmanDJacksonRWGrahamNMVlahovD 1996 Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157 1271 1278

60. ToossiZMayanja-KizzaHHirschCSEdmondsKLSpahlingerT 2001 Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 123 233 238

61. WoldayDHailuBGirmaMHailuESandersE 2003 Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians. Int J Tuberc Lung Dis 7 110 116

62. DayJHGrantADFieldingKLMorrisLMoloiV 2004 Does tuberculosis increase HIV load? J Infect Dis 190 1677 1684

63. MahanCSWalusimbiMJohnsonDFLancioniCCharleboisE 2010 Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS ONE 5 e9138 doi:10.1371/journal.pone.0009138

64. WilliamsBGGranichRDe CockKMGlaziouPSharmaA 2010 Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 107 19485 19489

65. BadriMWilsonDWoodR 2002 Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359 2059 2064

66. World Health Organization 2009 Global tuberculosis control 2009: epidemiology, strategy, financing Geneva World Health Organization

67. GandhiNRMollAPLallooUPawinskiRZellerK 2009 Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 50 37 43

68. SterlingTRPhamPAChaissonRE 2010 HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 50 Suppl 3 S223 S230

69. World Health Organization 2012 Guidance on couples HIV Testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples Geneva World Health Organization

70. WareNC 2011 What's love got to do with it?—a relationship framework for research on adherence to antiretroviral therapy (ART) as pre-exposure prophylaxis [abstract]. 6th International Conference on HIV Treatment and Prevention Adherence; 22–24 May 2011; Miami Beach, Florida

71. CohenMSMuessigKESmithMKPowersKKashubaAD 2012 Antiviral agents and HIV prevention: controversies, conflicts and consensus. AIDS. E-pub ahead of print doi:10.1097/QAD.0b013e3283543e83

72. HallettTBBaetenJMHeffronRBarnabasRde BruynG 2011 Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8 e1001123 doi:10.1371/journal.pmed.1001123

73. ReynoldsSJMakumbiFNakigoziGKagaayiJGrayRH 2011 HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy in Rakai, Uganda. AIDS 25 473 477

74. El-SadrWMCoburnBJBlowerS 2011 Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 25 2295 2299

75. EatonJWJohnsonLFSalomonJABärnighausenTBendavidE 2012 HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9 e1001245 doi:10.1371/journal.pmed.1001245

76. LingappaJRLambdinBBukusiEANgureKKavumaL 2008 Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 3 e1411 doi:10.1371/journal.pone.0001411

77. ChemaitellyHCreminISheltonJHallettTAbu-RaddadLJ 2012 Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect 88 51 57

78. TumwesigyeEBaetenJTumwebazeHKurthARevallJ 2011 Potential of household-based HIV counseling and testing as a platform for targeted referral to HIV prevention and care in Uganda [abstract]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 17–20 July 2011; Rome, Italy

79. Joint United Nations Programme on HIV/AIDS 2011 UNAIDS terminology guidelines Geneva Joint United Nations Programme on HIV/AIDS

80. PisaniEGarnettGPBrownTStoverJGrasslyNC 2003 Back to basics in HIV prevention: focus on exposure. BMJ 326 1384 1387

81. VickermanPFossAMPicklesMDeeringKVermaS 2010 To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis. AIDS 24 2563 2572

82. BoilyMCLowndesCAlaryM 2002 The impact of HIV epidemic phases on the effectiveness of core group interventions: insights from mathematical models. Sex Transm Infect 78 Suppl 1 i78 i90

83. CoteAMSobelaFDzokotoANzambiKAsamoah-AduC 2004 Transactional sex is the driving force in the dynamics of HIV in Accra, Ghana. AIDS 18 917 925

84. AlaryMLowndesCM 2004 The central role of clients of female sex workers in the dynamics of heterosexual HIV transmission in sub-Saharan Africa. AIDS 18 945 947

85. GouwsEWhitePJStoverJBrownT 2006 Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 82 Suppl 3 iii51 iii55

86. QuanVMChungALongHTDonderoTJ 2000 HIV in Vietnam: the evolving epidemic and the prevention response, 1996 through 1999. J Acquir Immune Defic Syndr 25 360 369

87. ParkLSSiraprapasiriTPeerapatanapokinWManneJNiccolaiL 2010 HIV transmission rates in Thailand: evidence of HIV prevention and transmission decline. J Acquir Immune Defic Syndr 54 430 436

88. LowndesCMAlaryMBelleauMBosuWKintinD 2008 West Africa HIV/AIDS epidemiology and response synthesis. Characterisation of the HIV epidemic and response in West Africa: implications for prevention Washington (District of Columbia) World Bank

89. NgMGakidouELevin-RectorAKheraAMurrayCJ 2011 Assessment of population-level effect of Avahan, an HIV-prevention initiative in India. Lancet 378 1643 1652

90. ShahmaneshMPatelVMabeyDCowanF 2008 Effectiveness of interventions for the prevention of HIV and other sexually transmitted infections in female sex workers in resource poor setting: a systematic review. Trop Med Int Health 13 659 679

91. McClellandLWanjeGKashongaFKibeLMcClellandRS 2011 Understanding the context of HIV risk behavior among HIV-positive and HIV-negative female sex workers and male bar clients following antiretroviral therapy rollout in Mombasa, Kenya. AIDS Educ Prev 23 299 312

92. BraunsteinSLUmulisaMMVeldhuijzenNJKestelynEIngabireCM 2011 HIV diagnosis, linkage to HIV care, and HIV risk behaviors among newly diagnosed HIV-positive female sex workers in Kigali, Rwanda. J Acquir Immune Defic Syndr 57 e70 e76

93. HuetCOuedraogoAKonateITraoreIRouetF 2011 Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. BMC Public Health 11 700

94. McClellandRSGrahamSMRichardsonBAPeshuNMaseseLN 2010 Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS 24 891 897

95. McKinnonLRKimaniMWachihiCNagelkerkeNJMuriukiFK 2010 Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS ONE 5 e11434 doi:10.1371/journal.pone.0011434

96. DeeringKNShannonKSinclairHParsadDGilbertE 2009 Piloting a peer-driven intervention model to increase access and adherence to antiretroviral therapy and HIV care among street-entrenched HIV-positive women in Vancouver. AIDS Patient Care STDS 23 603 609

97. ShannonKBrightVDuddyJTyndallMW 2005 Access and utilization of HIV treatment and services among women sex workers in Vancouver's Downtown Eastside. J Urban Health 82 488 497

98. ChanCHMcCabeCJFismanDN 2011 Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 88 200 204

99. KennedyCO'ReillyKMedleyASweatM 2007 The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 19 707 720

100. MontagueBTVuylstekeBBuveA 2011 Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention. BMC Public Health 11 701

101. VermaRShekharAKhobragadeSAdhikaryRGeorgeB 2010 Scale-up and coverage of Avahan: a large-scale HIV-prevention programme among female sex workers and men who have sex with men in four Indian states. Sex Transm Infect 86 Suppl 1 i76 i82

102. AlaryMMukenge TshibakaLBernierFGeraldoNLowndesCM 2002 Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993–1999. AIDS 16 463 470

103. GhysPDDialloMOEttiegne TraoreVKaleKTawilO 2002 Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Cote d'Ivoire, 1991–1998. AIDS 16 251 258

104. ChandrashekarSGuinnessLKumaranayakeLReddyBGovindrajY 2010 The effects of scale on the costs of targeted HIV prevention interventions among female and male sex workers, men who have sex with men and transgenders in India. Sex Transm Infect 86 Suppl 1 i89 i94

105. CreeseAFloydKAlbanAGuinnessL 2002 Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 359 1635 1643

106. VickermanPTerris-PrestholtFDelanySKumaranayakeLReesH 2006 Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa. Sex Transm Dis 33 Suppl 10 S122 S132

107. DiabateSZannouDGeraldoNChamberlandAAkakpoJ 2011 Antiretroviral therapy among HIV-1 infected female sex workers in Benin: a comparative study with patients from the general population. World J AIDS 1 94 99

108. Rodriguez-ArenasMAJarrinIdel AmoJIribarrenJAMorenoS 2006 Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 22 715 723

109. WattsCZimmermanCFossAMHossainMCoxA 2010 Remodelling core group theory: the role of sustaining populations in HIV transmission. Sex Transm Infect 86 Suppl 3 iii85 iii92

110. BoilyMCWilliamJAlaryM 2011 Impact of female sex worker turnover on HIV prevalence, incidence and core group intervention impact in Cotonou (Benin) [poster]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10–14 July 2011; Quebec City, Canada

111. PicklesMBoilyMCVickermanPRameshBMWashingtonR 2011 Time evolution of the fraction of new HIV infections due to primary infection among high risk groups in southern India [poster]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10–14 July 2011; Quebec City, Canada

112. VickermanPWattsCDelanySAlaryMReesH 2006 The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 33 397 405

113. BoilyMCLowndesCAlaryM 2000 Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS 14 2583 2592

114. GeibelSvan der ElstEMKing'olaNLuchtersSDaviesA 2007 ‘Are you on the market?’: a capture-recapture enumeration of men who sell sex to men in and around Mombasa, Kenya. AIDS 21 1349 1354

115. van GriensvenF 2007 Men who have sex with men and their HIV epidemics in Africa. AIDS 21 1361 1362

116. Joint United Nations Programme on HIV/AIDS 2010 New HIV infections by mode of transmission in West Africa: A multicountry analysis Geneva Joint United Nations Programme on HIV/AIDS

117. MathersBDegenhardtLPhillipsBWiessingLHickmanM 2008 Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 1733 1745

118. StrathdeeSAHallettTBBobrovaNRhodesTBoothR 2010 HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376 268 284

119. Joint United Nations Programme on HIV/AIDS 2009 KENYA HIV prevention response and modes of transmission analysis Geneva Joint United Nations Programme on HIV/AIDS

120. WolfeDCarrieriMPShepardD 2010 Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376 355 366

121. MaltaMMagnaniniMMStrathdeeSABastosFI 2010 Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 14 731 747

122. NdiayeBOuld-KaciKSalleronJBataillePBonnevieF 2009 Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France—January 1997 to December 2006. Antivir Ther 14 567 575

123. MocroftAKirkOAldinsPChiesABlaxhultA 2008 Loss to follow-up in an international, multicentre observational study. HIV Med 9 261 269

124. RosenSSanneICollierASimonJL 2005 Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med 2 e303 doi:10.1371/journal.pmed.0020303

125. GranichRGuptaSSutharABSmythCHoosD 2011 Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9 446 469

126. International Maternal Pediatric Adolescent AIDS Clinical Trials Group 2010 PROMISE featured study—1077HS. Available: https://impaactgroup.org/promise-featured-study-1077hs. Accessed June 8, 2012

127. CornellMGrimsrudAFairallLFoxMPvan CutsemG 2010 Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS 24 2263 2270

128. NachegaJBMorroniCZunigaJMSchechterMRockstrohJ 2012 HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010 AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care (Chic) 11 128 133

129. ThompsonMAMugaveroMJAmicoKRChangLWGrossR 2012 Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. Ann Intern Med 156 817 833

130. World Health Organization 2003 Making choices in health: generalized cost effectiveness analysis: a guide Geneva World Health Organization

131. World Health Organization 2011 WHO consultation on the strategic use of antiretrovirals for treatment and prevention of HIV Geneva World Health Organization

132. LewdenCGabillardDMingaAEkoueviDKAvitD 2012 CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa. J Acquir Immune Defic Syndr 59 213 219

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2012 Číslo 7
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#